Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07833878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chinese Hemoptysis Registry Study (CHORE)

Study acronym: CHORE
StatusNot Yet Recruiting
PhaseNot specified
SponsorQiu Jipeng
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date pushed from Sep 1, 2026 to Oct 10, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Baseline clinical, imaging, angiographic, procedural, and in-hospital outcome data will be collected, and patients will be followed at 1 and 3 months and every 6 months for at least 2 years. The study aims to describe the real-world epidemiology and etiology spectrum of hemoptysis in China, evaluate short- and long-term outcomes of interventional therapy, identify independent risk factors for recurrence, and build a recurrence prediction model to support standardized diagnosis and treatment of hemoptysis.
Trial Details
NCT Number NCT07833878
Lead Sponsor Qiu Jipeng
Conditions
(from sponsor)		 Hemoptysis
Related terms Hemoptysis
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov